Daxor Co. (NASDAQ:DXR) Sees Large Increase in Short Interest

Daxor Co. (NASDAQ:DXR) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 9,000 shares, an increase of 7.1% from the December 15th total of 8,400 shares. Based on an average daily volume of 16,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.5% of the shares of the stock are sold short.

Daxor Trading Up 5.1 %

Shares of NASDAQ DXR opened at $8.50 on Tuesday. Daxor has a 52 week low of $7.19 and a 52 week high of $10.02. The firm has a 50-day moving average price of $8.55 and a 200 day moving average price of $8.80.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its holdings in Daxor Co. (NASDAQ:DXR) by 34.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities and Exchange Commission. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.